Company Overview

Update
Founded:
2004
Headquarters:
Kalamazoo, MI
Funding:
$77.5M
Categories:
Biotechnology
Description:
ProNAi Therapeutics is a biotech company leveraging its proprietary nucleic acid-based interfering technology, DNAi®, for cancer patients.

Detailed Description

Update

ProNAi Therapeutics is applying proprietary, nucleic acid-based DNA interference technology (DNAi®) to discover and develop novel therapeutic approaches for cancer and other diseases. The company was founded in 2004 by pharmaceutical researchers and scientists who have substantial experience in the area of nucleic acid research in cancer. The company's most advanced drug candidate, PNT2258, has striking clinical and preclinical activity in hematological and solid tumor models.

ProNAi received approval to proceed into Phase 1 clinical testing from the FDA for PNT2258 and in September 2010 began those trials. The safety and efficacy results from the Phase I study conducted at START in Texas in refractory solid tumor patients were presented at EORTC in November 2012. Phase II trials are well underway in refractory NHL patients at clinical sites in the Midwest.

The company has successfully recruited a seasoned senior management team and a Board of Directors with a proven track record in research, clinical operations, product development, and business development. ProNAi's Scientific and Medical Advisory Board has significant experience in cancer, nucleic acid research, and clinical trial design and development.

Current Team (1)

Update

Past Team (1)

Update

Funding Rounds (4) - $77.5M

Update

Investors (9)

Update

Offices/Locations (2)

Update
  • Office

    46701 Commerce Center Drive

    Plymouth, 48170

  • Office

    4717 Campus Drive

    Suite 1100

    Kalamazoo, MI 49008

    USA

Images (1)

Update
  • Liwxttwjycl9fv3wx7iu